No Cover Image

Journal article 101 views 21 downloads

Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer

Pete Arnold Orcid Logo, Maria Cristina Penaloza-Ramos, Lola Adedokun, Sarah Rees, Mohamed Lockhat, Lisa Spary, Alan Watkins Orcid Logo, Vincent Gnanapragasam, Simon J. Crabb

Scientific Reports, Volume: 11, Issue: 1, Start page: 22151

Swansea University Authors: Pete Arnold Orcid Logo, Sarah Rees, Alan Watkins Orcid Logo

  • 41598_2021_Article_1042.pdf

    PDF | Version of Record

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

    Download (2.48MB)

Abstract

This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patien...

Full description

Published in: Scientific Reports
ISSN: 2045-2322
Published: Springer Science and Business Media LLC 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa58658
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patient record, termed non-metastatic castration-resistant PC (nmCRPC). Routinely collected administrative data in Wales were used to identify patients diagnosed with PC and nmCRPC from 2000–2015. Logrank tests and Cox proportional hazard models were used to compare time-to-events across subgroups defined by PSA doubling time and age. Of 38,021 patients identified with PC, 1,465 met nmCRPC criteria. PC incidence increased over the study period, while nmCRPC categorizations reduced. Median time from PC diagnosis to nmCRPC categorization was 3.07 years (95% confidence interval [CI] 2.91–3.26) and from nmCRPC categorization to metastases/death was 2.86 years (95% CI 2.67–3.09). Shorter PSA doubling time (≤ 10 months, versus > 10 months) was associated with reduced time to metastases or death (2.11 years [95% CI 1.92–2.30] versus 5.22 years [95% CI 4.87–5.51]). Age was not significantly associated with time to metastases/death. Our findings highlight key clinical characteristics and outcomes for patients with nmCRPC prior to the introduction of recently approved treatments.
College: Swansea University Medical School
Funders: Janssen-Cilag Ltd
Issue: 1
Start Page: 22151